Diligence memo · auto-generated · as of July 2, 2026
Anubis Bio Corp.
Anubis Bio Corp. looks over-valued against its niche peers and is dormant on financing cadence.
Businessfiled
Anubis Bio Corp. operates in Biotech / Pharma, based in OVIEDO.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
Anubis Bio Corp. has raised $300K in disclosed capital across 1 recorded round, aggregated from public filings. Its latest round is modeled as Pre-Seed (a round under $1.0M).
Largest single filing: $300K on 2019-06-07.
Most recent recorded round closed around 2019-06-07.
Valuation (modeled)modeled
Provath models Anubis Bio Corp. at approximately $15M (range $164K–$174M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Over-valued. Modeled value is 3.00× the median modeled value of Pre-Seed Biotech / Pharma companies in 2019–2021 (15 peers) — value vs value, same stage and era.
Financing rhythm & timingmixed
Last raise 7.1 yr ago; this sector typically re-raises about every 15 months.
Only one round on record and long silent — often defunct, acquired, or gone quiet.
Comparablesmixed
Capital scale ranks ahead of 19% of Biotech / Pharma peers (227 compared).
Modeled value ranks above 37% of those peers.
Closest niche peers: AbX Biologics, Inc., BC Green Pharmaceuticals Inc., Platinum Biosciences, Inc., Green Star Biosciences Inc., Nexus Biologics, SPC.
Peoplefiled
1 named person on file across officers, directors and signatories.
Risks & flagsmixed
Financing has been silent well beyond sector cadence — possibly defunct, acquired, or paused.
Modeled above niche peers — valuation risk on entry.
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.